HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Polycyclic Compounds (Compounds, Polycyclic)

Subscribe to New Research on Polycyclic Compounds

Share|Follow on Twitter

Compounds consisting of two or more fused ring structures.

Also Known As:

Compounds, Polycyclic; Hydrocarbons, Polycyclic; Polycyclic Hydrocarbons

Networked: 55 relevant articles (1 outcomes, 1 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 55

Experts

1.	Thornhill, Brent A: 1 article (12/2012)
2.	Santanam, Nalini: 1 article (12/2012)
3.	Lau, Jamie K: 1 article (12/2012)
4.	Dasgupta, Piyali: 1 article (12/2012)
5.	Crabtree, Clayton M: 1 article (12/2012)
6.	Cook, Carla R: 1 article (12/2012)
7.	Brown, Kathleen C: 1 article (12/2012)
8.	Mirabelli, Dario: 1 article (11/2009)
9.	van Dyk, Sandra: 1 article (10/2008)
10.	Malan, Sarel F: 1 article (10/2008)

Related Diseases

1.	Lung Neoplasms (Lung Cancer) 11/01/2009 - "An improved estimate of the quantitative relationship between polycyclic hydrocarbons and lung cancer." 01/01/1990 - "Exposure to polycyclic hydrocarbons adsorbed on industrial dust was shown to significantly increase the incidence of lung cancer." 07/01/1996 - "Risks of lung cancer appeared increased for a variety of jobs throughout the complex, especially those with probable high levels of exposure to polycyclic hydrocarbons and asbestos. " 01/01/1981 - "Possible contribution of polycyclic hydrocarbons, trace metals, and gaseous pollutants to the incidence of lung cancer in the urban populations has been considered, including the role of carcinogens in the cigarette smoke. " Order ALL the reference details at left...
2.	Neoplasms (Cancer) 09/01/2004 - "Certain hazardous occupational exposures (polycyclic hydrocarbons, paints and lacquer, stone dust) may play a role in modulating tumor angiogenesis. " 09/01/1987 - "Further investigations into the effect of non-benzo ring bay-region methyl substituents on tumor-initiating activity of polycyclic hydrocarbons." 01/15/1979 - "[The problem of relationship between the exposure to polycyclic hydrocarbons and the incidence of cancer in 2 chemical plants of Thuringia]." 04/06/1978 - "The metabolism of polycyclic hydrocarbons and its relationship to cancer." 01/01/1971 - "Characteristics of primary tumors induced by carcinogenic polycyclic hydrocarbons in Syrian hamsters." Order ALL the reference details at left...
3.	Xeroderma Pigmentosum (Kaposi's Disease) 01/01/1981 - "Cells that appeared capable of metabolizing polycyclic hydrocarbons or aromatic amines by these methods were also found to produce metabolites which were cytotoxic to cocultivated human xeroderma pigmentosum fibroblasts after a 48-hr exposure to the carcinogen." 01/01/1975 - "Cytotoxic and mutagenic effects of carcinogenic aromatic amides and polycyclic hydrocarbons and ultraviolet irradiation in normally repairing and repair-deficient (xeroderma pigmentosum) diploid human skin fibroblasts." 04/01/1977 - "The cytotoxicity of the "K-region" epoxides as well as several other reactive metabolites or chemical derivatives of polycyclic hydrocarbons was compared in normally-repairing human diploid skin fibroblasts and in fibroblasts from a classical xeroderma pigmentosum (XP) patient (XP2BE) whose cells have been shown to carry out excision repair of damage induced in DNA by ultraviolet (UV) radiation at a rate approx. " Order ALL the reference details at left...
4.	Hyperplasia 02/01/1985 - "The second system, an explant culture technique using foetal tracheae, demonstrated the induction, by polycyclic hydrocarbons, of alterations such as hyperplasia, epidermoid metaplasia or dysplasia of mucociliary epithelia. " 05/01/1991 - "Histological evidence of thyroid follicular hyperplasia has been noted in rats after administration of phenobarbital, nicardipine, polycyclic hydrocarbons, and possibly an experimental imidazole. " 12/01/1975 - "Hyperplasia, papilloma and carcinoma formation induced by topical application of the carcinogenic polycyclic hydrocarbons benz(a)pyrene (B(a)P) and 3-methylcholanthrene (MC) is accompanied by an increase in the mumber of A particles. " Order ALL the reference details at left...
5.	Hepatocellular Carcinoma (Hepatoma) 11/01/1983 - "Activation of polycyclic hydrocarbons in Reuber H4-II-E hepatoma cells. " 01/01/1982 - "We compared our data with various parameters taken from previously published results: the capacity of seven polycyclic hydrocarbons to induce aryl hydrocarbon hydroxylase (AHH) activity in human cell cultures, the capacity of 10 polycyclic hydrocarbons to induce azo dye N-demethylase activity in rat liver, the capacity of 6 polycyclic hydrocarbons to shorten zoxazolamine paralysis times in the intact rat, and the capacity of 15 benzo[a]pyrene metabolites to induce AHH activity in rat hepatoma H-4-II-E cultures. " 12/01/1990 - "Further characterization revealed the following additional differences among these three factors: (i) XF1 and XF2 could be extracted from nuclei under conditions quite different from those required for extraction of the Ah receptor; (ii) XF1 and XF2 were present in the nuclei of untreated cells and did not respond to polycyclic compounds, such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and beta-napthoflavone, while nuclear Ah receptor was undetectable in untreated cells and rapidly increased in response to TCDD; (iii) inhibition of protein synthesis did not affect the TCDD-induced appearance of the Ah receptor but substantially decreased the constitutive activities of XF1 and XF2, suggesting that the Ah receptor must be present in untreated cells in an inactive form that can be rapidly activated by polycyclic compounds, while the constitutive expression of XF1 and XF2 depends on the continued synthesis of a relatively unstable protein; (iv) the receptor-deficient and nuclear translocation-defective mutants of the hepatoma cell line Hepa1, which are known to lack nuclear Ah receptor, expressed normal levels of XF1 and XF2, suggesting that the former factor is genetically distinct from the latter two; and (v) a divalent metal ion, probably Zn2+, is known to be an essential cofactor for the Ah receptor but was not required for the DNA-binding activities of XF1 and XF2. " 01/01/1982 - "differences in the rate of cellular uptake and formation of alkali-extractable metabolites of dibenzo[a,h]anthracene, 3-methylcholanthrene, and benzo[a]anthracene in Hepa-1 mouse hepatoma cell cultures do not account for differences in the capacity of these three polycyclic hydrocarbons to displace [3H]TCDD from the Ah receptor." Order ALL the reference details at left...

Related Drugs and Biologics

1.	Cytochrome P-450 CYP1A1 (CYP1A1)
2.	Carcinogens
3.	Benzo(a)pyrene
4.	Amines
5.	Tetrachlorodibenzodioxin (TCDD)
6.	DNA (Deoxyribonucleic Acid)
7.	Nitrosamines
8.	Cytochrome P-450 Enzyme System (Cytochrome P450)
9.	anthracene
10.	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)

blog comments powered by Disqus

TREATMENT OPTIONS
for Lung Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 1036 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$24.95 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$490.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>